Finasteride vs Minoxidil
FDA Approved vs FDA Approved
synergistic Gold-standard combination for hair loss treatment. Finasteride reduces DHT-mediated miniaturization while minoxidil stimulates follicular blood flow and prolongs the anagen phase. Studies show significantly better outcomes with the combination than either agent alone.
Molecular Data
Finasteride Minoxidil
Weight 372.54 Da 209.25 Da
Half-life 6-8 hours (DHT suppression persists ~24 hours) ~4 hours (oral); topical effects persist significantly longer due to local tissue retention
Type Synthetic 4-azasteroid compound Synthetic pyrimidine derivative (6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine)
Key Benefits
Finasteride
01 Reduces scalp DHT by approximately 66% at 1mg daily
02 Slows or stops hair loss progression in roughly 90% of men
03 Produces visible hair regrowth in approximately 48% of men within 1-2 years
04 FDA-approved with over 25 years of clinical use and long-term safety data
05 Convenient once-daily oral dosing with no injections required
06 Well-characterized side effect profile with low incidence of adverse events
07 Can be combined with minoxidil for enhanced efficacy
Minoxidil
01 FDA-approved for androgenetic alopecia with decades of clinical evidence
02 Stimulates new hair growth and increases hair follicle size independent of androgen pathways
03 Available over the counter as a topical treatment without a prescription
04 Effective in both men and women for pattern hair loss
05 Low-dose oral formulation offers a convenient once-daily alternative to twice-daily topical application
06 Synergistic with finasteride and dutasteride for a multi-mechanism approach to hair loss
07 Extends the anagen (growth) phase and shortens the telogen (resting) phase of the hair cycle
Side Effects
Finasteride
Decreased libido (reported in 1.8% of men in clinical trials vs 1.3% placebo)
Erectile dysfunction (reported in 1.3% vs 0.7% placebo)
Decreased ejaculate volume (reported in 0.8% vs 0.4% placebo)
Minoxidil
Scalp irritation, dryness, or flaking (topical, especially solution formulations containing propylene glycol)
Initial shedding phase during the first 1-3 months of treatment
Hypertrichosis (unwanted facial and body hair growth, more common with oral administration)
Fluid retention and mild peripheral edema (oral)
Mild dizziness or lightheadedness upon standing (oral, due to vasodilation)
Contraindications
Women who are pregnant or may become pregnant (finasteride is teratogenic and can cause abnormalities of external genitalia in a male fetus; even handling crushed tablets poses a risk)
Women who are breastfeeding
Known hypersensitivity to finasteride or any component of the formulation
Severe hepatic impairment (finasteride is metabolized by the liver)
Pediatric patients (not indicated for use in children)
Known hypersensitivity to minoxidil or any component of the formulation
Pheochromocytoma (minoxidil may stimulate catecholamine release)
Significant cardiovascular disease, including history of pericardial effusion or congestive heart failure
Concurrent use of potent antihypertensive medications without physician supervision (risk of additive hypotension)
Pregnancy and breastfeeding (Category C; oral minoxidil has shown evidence of fetal harm in animal studies)
Research Evidence
Finasteride Minoxidil
Status FDA Approved FDA Approved
References 5 studies 5 studies
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.